Healthcare Industry News:  oral cancer 

Diagnostics Oncology

 News Release - December 18, 2006

Zila, Inc. Announces Resignation of Andrew Stevens, Chief Financial Officer

Diane E. Klein, Vice President of Finance and Treasurer, to Assume Interim Responsibilities

PHOENIX--(HSMN NewsFeed)--Zila, Inc.'s (Nasdaq GM: ZILA) Chief Financial Officer, Andrew Stevens, has resigned to pursue other opportunities. Diane Klein, Zila's Vice President and Treasurer, will take over responsibilities until a new CFO is appointed.

Douglas D. Burkett, Ph.D., Chairman, Chief Executive Officer and President of Zila, said, "We are thankful to Andy for his many contributions to Zila as we transformed the Company into a cancer detection business. We wish him well in his future endeavors."

Dr. Burkett continued, "Diane Klein has been an integral part of our finance team since she joined the Company more than three years ago. With a strong background in finance and public accounting, we are confident in her ability to immediately assume the required financial responsibilities while we conduct our search for a new Chief Financial Officer."

About Zila, Inc.

Zila, Inc., headquartered in Phoenix, is a leading cancer diagnostic company focused on oral cancer:

Zila Pharmaceuticals is dedicated to establishing ViziLite® Plus as the new standard of care for the early detection of oral abnormalities that could lead to cancer, with initial focus on the dental market through Pro-Dentec®, a leading designer, manufacturer and marketer of products sold exclusively to dental professionals for Soft Tissue Management ("STM®") including the Rota-dent® Professional Powered Brush, the Pro-Select3® Piezo-Ultrasonic Scaler System and a suite of pharmaceutical STM® products for both in-office and home-care use.

Zila Biotechnology is focused on achieving regulatory approval for the next generation oral cancer diagnostic, OraTest®, followed by the development of additional applications of its cancer detection technologies. For more information about Zila, visit

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on Zila's expectations or forecasts of future events, can be affected by inaccurate assumptions and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the Company's control. Therefore, actual results could differ materially from the forward-looking statements contained herein. A wide variety of factors could cause or contribute to such differences and could adversely impact revenues, profitability, cash flows and capital needs. There can be no assurance that the forward-looking statements contained in this press release will, in fact, transpire or prove to be accurate. The Company makes no commitment, and disclaims any duty, to update or revise any forward-looking statements to reflect future events or changes in expectations. For a more detailed description of these and other cautionary factors that may affect Zila's future results, please refer to Zila's Form 10-K for its fiscal year ended July 31, 2006 and subsequent filings we make with the Securities and Exchange Commission.

Source: Zila, Inc

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.